- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020
In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.
Recently, Pfizer announced its pegfilgrastim biosimilar (Nyvepria) was approved by the FDA, which marks the first biosimilar approval this year. Although many expected more approvals earlier in the year, experts wonder if the race to find a revolutionary treatment and vaccine for coronavirus disease 2019 (COVID-19) slowed down the approval process and biosimilars have had to take a back seat for the time being.
We sat down with Nick Mitrokostas, an intellectual property lawyer and partner at Goodwin's IP Litigation group, to discuss how this new approval will affect the biosimilar market and what he sees for the rest of 2020.
To learn more about the approval of Nyvepria, check out our article on it here.
To learn more about Goodwin Proctor LLP, visit goodwinlaw.com
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
